WO2026101464 - VIRUSES NEUTRALIZATION THROUGH A OXIDATION- REDUCTION REACTION ON THE VIRUS ENVELOPE
National phase entry is expected:
Publication Number
WO/2026/101464
Publication Date
15.05.2026
International Application No.
PCT/SK2025/000014
International Filing Date
04.11.2025
Title **
[English]
VIRUSES NEUTRALIZATION THROUGH A OXIDATION- REDUCTION REACTION ON THE VIRUS ENVELOPE
[French]
NEUTRALISATION DE VIRUS PAR RÉACTION D'OXYDORÉDUCTION SUR L'ENVELOPPE VIRALE
Applicants **
EUROPEAN INSTITUTE OF TECHNOLOGIES, S. R. O.
Inventors
TARASOV, Oleksandr
TARASENKO, Volodymyr
NOGA, David
LYSAYCHUK, Yuriy
KUMAR, Anurag
Priority Data
PP90-2024
11.11.2024
SK
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1882 | |
| EPO | Filing, Examination, Granting | 8107 | |
| Japan | Filing, Examination, Granting | 1722 | |
| South Korea | Filing, Examination, Granting | 1190 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
17,641
Contact Us
Abstract[English]
The name of the invention: "Neutralization of viruses through oxidation-reduction reaction on the virus envelope" suggests its use in medicine, both in the human and animal fields. This is not only a specific use, but also from the point of view of the dosage regimen, the method of dosage, a new group of patients, of component No. 1 - Cu2+ obtained in a solution of copper sulfate pentahydrate in distilled water, where copper must have at least two free ions and component No. 2 - L-ascorbic acid for neutralization of viruses through oxidation-reduction reaction on the virus envelope, which is characterized by the fact that it ensures the destruction of the virus envelope and thus the inhibition of viruses in humans and other warm-blooded animals. Both substances are administered in a non-toxic concentration appropriate for the human and animal organism and with an appropriate time interval, so that the most suitable conditions for the oxidation-reduction reaction on the virus envelope are created and maintained. The use of these two components establishes a scientifically proven premise for the successful prevention and treatment of infection with various types of enveloped viruses and the diseases they cause.[French]
Le nom de l'invention : « neutralisation de virus par réaction d'oxydoréduction sur l'enveloppe virale » suggère son utilisation en médicíne, à la fois dans les domaines humain et animal. L'invention concerne non seulement une utilisation spécialisée, mais également du point de vue du schéma posologique, de la méthode d'administration, d'un nouveau groupe de patients, du composant n ° 1 - Cu2+ obtenu dans une solution de sulfate de cuivre pentahydraté dans de l'eau distillée, où le cuivre doit avoir au moins deux ions libres et du composant n ° 2 - acide L-ascorbique pour la neutralisation de virus par réaction d'oxydoréduction sur l'enveloppe virale, qui est caractérisée en ce qu'elle garantit la destruction de l'enveloppe virale et donc, l'inhibition de virus chez l'humain et d'autres animaux à sang chaud. Les deux substances sont administrées à une concentration non toxique appropriée pour l'organisme humain et animal et à un intervalle de temps approprié, de sorte que les conditions les plus appropriées pour la réaction d'oxydoréduction sur l'enveloppe virale sont établies et maintenues. L'utilisation de ces deux composants établit un principe scientifiquement prouvé pour la prévention et le traitement efficaces d'une infection par divers types de virus enveloppés et des maladies qu'ils provoquent.